Quantcast
Home > Quotes > CYCC
x
CYCC

Cyclacel Pharmaceuticals, Inc. Common Stock (CYCC) Quote & Summary Data

$1.3999
*  
0.0099
0.71%
Get CYCC Alerts
*Delayed - data as of Oct. 17, 2018 14:08 ET  -  Find a broker to begin trading CYCC now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    CYCC Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 1.38 / $ 1.40
1 Year Target
7
Today's High / Low
$ 1.44 / $ 1.3899
Share Volume
17,964
50 Day Avg. Daily Volume
77,062
Previous Close
$ 1.39
52 Week High / Low
$ 2.25 / $ 1.281
Market Cap
16,795,226
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.13

Intraday Chart

Shares Traded

Share Volume:
17,964
50 Day Avg. Daily Volume:
77,062

Trading Range

The current last sale of $1.3999 is 9.28% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.44 $ 2.25
 Low: $ 1.3899 $ 1.281

Company Description (as filed with the SEC)

The following Business Section contains forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain risks, uncertainties and other factors including the risk factors set forth in Part I, Item 1A of this Annual Report on Form 10-K. In this report, "Cyclacel," the "Company," "we," "us," and "our" refer to Cyclacel Pharmaceuticals, Inc. General Cyclacel is a clinical-stage biopharmaceutical company using cell cycle control, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. Cyclacel is a pioneer company in the field of cell cycle biology with a vision to improve patient healthcare by translating cancer biology into medicines. Our strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates.  ... More ...  


Risk Grade

Where does CYCC fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.40
Open Date:
Oct. 17, 2018
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info